Whitehead's reminder made Old Jack frown. The government intended to promote the domestic pharmaceutical industry to develop into large companies, and he had heard some rumors earlier.

It's a matter of self-interest that no one will ignore.

And he also knew that the company's second largest shareholder wanted to gain control of the company precisely for this reason.

Because only by gaining control of the company can we decide which path the company should take next.

Since the government intends to promote it, there are only two paths for Shire to take, one is to merge with other pharmaceutical companies, and the other is to wait to be merged by other pharmaceutical companies.

Whether the two merge or are merged, there are huge benefits to be gained.

Because Old Jack is the founder and shareholder of the company, and directly controls the research laboratory, he has great prestige within the company, and has been able to support it until now without being succeeded by the conspiracy of the second largest shareholder.

As a Wall Street elite, Whitehead is the one who knows the top-level decisions of the government best. Since the other party said this, it means that it is now the general trend.

Although Old Jack is old, there is nothing wrong with his brain. He still knows the principle of retreat if you don't advance.

If Shire continues to remain unchanged, it will sooner or later be surpassed by the pharmaceutical companies around it. Once large interest groups are formed, the interests of small and medium-sized enterprises will be compressed to the extreme.

By then, the loss of power will be a small matter, and the company may have to be acquired by outsiders.

Old Jack was silent for a while and then said: "Heite, I understand what you mean. I will seriously consider this matter when I go back. I may need to trouble you again."

After the listing of Orange Technology, Goldman Sachs gained a lot of fame. Even in the United States, a country full of financial investment banks, only a few companies can raise tens of billions of dollars in financing.

In recent years, there has been a wave of foreign investment in the U.S. market. After this battle, it goes without saying that those foreign companies that want to be listed in the United States will think of Goldman Sachs immediately.

Goldman Sachs became famous in one fell swoop, and Whitehead, a senior partner at Goldman Sachs, naturally followed suit.

Seeing that Old Jack's expression softened, Whitehead finally relaxed and said quickly: "Uncle, your matter is my matter. If you need it, you can contact me at any time."

"However, I think uncle, if you are determined to expand the scale of Shire Company, then you must never forget the big financial backer sitting next to you."

"Press?" Old Jack was stunned for a moment, then followed Whitehead's line of sight and saw Yang Chen drinking in silence, as if he didn't hear the conversation between the two and didn't answer.

After Whitehead's reminder, Old Jack quickly understood what it meant, and the look he looked at Yang Chen was a little different.

Seeing that Yang Chen did not respond, Whitehead continued: "As far as I know, Yang has invested in many American pharmaceutical companies, including several well-known pharmaceutical companies. The stocks he holds have already

Enough to join the board of directors and participate in shareholder decision-making meetings."

"If my uncle wants to raise funds, he can raise funds internally first. I think Yang will definitely not reduce the shares he holds, and may even increase his shares."

Whitehead spoke with a very firm tone, obviously knowing that Yang Chen would not give up on Shire Pharmaceutical Company.

"Ahem!" After hearing this, Yang Chen glared at Whitehead angrily, with a somewhat sarcastic tone, and said: "Whitehead, you've had enough of being a Wall Street elite, and you're going to change your profession to learn to be a priest.

Yes, right?"

Whitehead did not defend himself and said directly: "Yang, actually, even if you don't tell me, I also know that your purpose of investing in so many pharmaceutical companies in the United States is not to hold a controlling stake or to participate in the internal management of the company."

"Your target is in Asia, not the United States. It can be said that there is no conflict of interest between you and your uncle. In this case, why can't we cooperate further?"

Yang Chen did not answer the call because the other party was right. He had invested in an American pharmaceutical company and had no intention of controlling it or participating in their internal management.

Of course, even if he wanted to, for a well-known pharmaceutical company like Shire, under normal circumstances the US government would not allow foreign investors to control it.

The medical system is related to the lives and health of the American people. Allowing foreign-funded enterprises to control it is tantamount to handing over the lives and health of hundreds of millions of American people to outsiders.

For Americans, this is absolutely unacceptable.

The United States’ external propaganda has always emphasized how open and free it is. However, in fact, the United States’ protection of some sensitive industries and companies is unparalleled by any country in the world.

In later generations, the United States often used the words "endangering national security" to impose various restrictions on foreign businessmen, which can be said to be detrimental to all.

The United States is now preparing to vigorously promote the domestic pharmaceutical industry, and naturally will not allow its own pharmaceutical companies to be controlled by foreign capital.

Yang Chen has invested in many pharmaceutical companies in the United States. In addition to waiting for the stocks of these pharmaceutical companies to appreciate, the other thing is to take this opportunity to obtain the medical achievements of the companies he invests in.

Compared with the U.S. pharmaceutical market, which is mature and stable and has a great role in promoting drug research and development, Asia is in a developing state and has a variety of problems in the pharmaceutical industry.

The development of medicines requires a lot of time and money, which also requires a large number of research and development personnel.

Cultivating a pharmaceutical R&D team does not happen overnight.

Although Asia accounts for nearly two-thirds of the world's population, its pharmaceutical industry really cannot compare with that of the United States.

The United States is a highly developed country with a large population and a complete medical insurance system, which provides the market needed for American pharmaceutical companies.

With huge market profit returns, American pharmaceutical companies can increase research and development efforts. This virtuous cycle is lacking in most Asian countries.

In later generations, the United States was the most successful country in implementing a free pricing system. The price of medicines was mainly determined by the overall trend of market supply and demand.

The pricing mechanism in the United States gives pharmaceutical companies greater pricing autonomy, especially companies with monopoly products, which basically enjoy monopoly pricing rights.

The biggest benefit of this system is that it can effectively promote the speed and intensity of drug research and development.

Although there was also strong opposition to high drug prices in the United States in later generations, this voice did not cause major social problems. This is mainly due to the relatively sound medical insurance system in the United States.
Chapter completed!